Aurinia Pharmaceuticals Inc (AUPH) vs NewAmsterdam Pharma Company N.V. (NAMS)
- Aurinia Pharmaceuticals Inc AUPH 16.51 −1.32%
- NewAmsterdam Pharma Company N.V. NAMS 19.83 −3.83%
Aurinia Pharmaceuticals Inc and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. is the larger, with a market value of $2.5B against $2.2B — 1.1× the size. NewAmsterdam Pharma Company N.V. has negative trailing earnings, so its P/E is not meaningful; Aurinia Pharmaceuticals Inc trades at 6.9×. Aurinia Pharmaceuticals Inc grew revenue faster over the last twelve months: 19.8% against −88.9%. Aurinia Pharmaceuticals Inc has the higher net margin (100.8% vs −3,644.2%) and the higher return on invested capital (40.8% vs 0.00%). Across the 17 metrics below, Aurinia Pharmaceuticals Inc leads on 14 and NewAmsterdam Pharma Company N.V. on 3.
Valuation
Profitability
| Metric | AUPH | NAMS | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.36% | 100.00% | 65.16% |
| Operating margin | 45.15% | (3,432.20%) | 0.00% |
| Net margin | 100.84% | (3,644.21%) | 0.00% |
| Free cash flow margin | 56.20% | (2,018.28%) | 0.00% |
| Return on equity | 66.12% | (36.81%) | (56.36%) |
| Return on assets | 48.52% | (34.16%) | (48.04%) |
| Return on invested capital | 40.76% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack